<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03360760</url>
  </required_header>
  <id_info>
    <org_study_id>PKUPH-OS-01</org_study_id>
    <nct_id>NCT03360760</nct_id>
  </id_info>
  <brief_title>Timing of Surgery in Nonmetastatic Osteosarcoma of the Pelvis and Sacrum</brief_title>
  <official_title>Presurgical Chemotherapy Compared With Immediate Surgery and Adjuvant Chemotherapy for Nonmetastatic Osteosarcoma of the Pelvis and Sacrum</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Peking University People's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Peking University People's Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To study the effect of the timing of surgery on outcome of patients with nonmetastatic
      osteosarcoma of pelvis and sacrum.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Successful therapeutic interventions to prevent disease progression in patients with
      nonmetastatic osteosarcoma of pelvis and sacrum have included surgery with adjuvant
      chemotherapy. Pre-surgical chemotherapy has been advocated for these patients because of
      putative improvement in event-free survival (EFS). The advantages of pre-surgical
      chemotherapy include early administration of systemic chemotherapy, shrinkage of primary
      tumor, and pathologic identification of risk groups. The theoretic disadvantage is that it
      exposes a large tumor burden to marginally effective chemotherapy, especially in the axial
      region. The contribution of chemotherapy and surgery timing has not been tested rigorously.
      To study the effect of the timing of surgery on outcome of patients with nonmetastatic
      osteosarcoma of pelvis and sacrum, we conducted multicenter randomized trial to determine
      whether chemotherapy administered before definitive resection of primary tumors improved EFS
      and overall survival compared with traditional resection of the primary tumor followed by
      adjuvant chemotherapy.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 2018</start_date>
  <completion_date type="Anticipated">February 2025</completion_date>
  <primary_completion_date type="Anticipated">February 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>5 years</time_frame>
    <description>Calculated from the date of treatment start until death, whichever comes first.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival (PFS)</measure>
    <time_frame>5 years</time_frame>
    <description>Calculated from the date of treatment start until the time of disease progression or death, whichever comes first.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tumor necrosis rate</measure>
    <time_frame>5 years</time_frame>
    <description>The percentage of tumor necrosis calculated in the resected specimen in Arm 2.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Osteosarcoma of Pelvis</condition>
  <arm_group>
    <arm_group_label>Pre surgical Chemotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Immediate pre surgical chemotherapy treated with four drugs including doxorubicin, cisplatin, high-dose methotrexate (MTX) and ifosfamide in eleven weeks, and then definitive surgery followed by adjuvant chemotherapy according to chemotherapy regimen in Peking University People's Hospital(PKUPH).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Immediate Surgery</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Immediate definitive surgery, and then post operative chemotherapy based on doxorubicin, cisplatin, high-dose MTX and ifosfamide according to chemotherapy regimen in PKUPH.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Doxorubicin</intervention_name>
    <description>60mg/m^2, in the adjuvant chemotherapy regimen for osteosarcoma in PKUPH</description>
    <arm_group_label>Pre surgical Chemotherapy</arm_group_label>
    <arm_group_label>Immediate Surgery</arm_group_label>
    <other_name>Adriamycin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin</intervention_name>
    <description>100mg/m^2, in the adjuvant chemotherapy regimen for osteosarcoma in PKUPH</description>
    <arm_group_label>Pre surgical Chemotherapy</arm_group_label>
    <arm_group_label>Immediate Surgery</arm_group_label>
    <other_name>cisplatinum</other_name>
    <other_name>platamin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methotrexate</intervention_name>
    <description>High dose of methotrexate (8-12g/m^2), in the adjuvant chemotherapy regimen for osteosarcoma in PKUPH</description>
    <arm_group_label>Pre surgical Chemotherapy</arm_group_label>
    <arm_group_label>Immediate Surgery</arm_group_label>
    <other_name>HD-MTX</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ifosfamide</intervention_name>
    <description>12g/m^2, in the adjuvant chemotherapy regimen for osteosarcoma in PKUPH</description>
    <arm_group_label>Pre surgical Chemotherapy</arm_group_label>
    <arm_group_label>Immediate Surgery</arm_group_label>
    <other_name>ifosphamide</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>definitive surgery</intervention_name>
    <description>Including limb-sparing procedure and amputation</description>
    <arm_group_label>Pre surgical Chemotherapy</arm_group_label>
    <arm_group_label>Immediate Surgery</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>pre surgical chemotherapy</intervention_name>
    <description>chemotherapy that given before definitive surgery</description>
    <arm_group_label>Pre surgical Chemotherapy</arm_group_label>
    <other_name>neoadjuvant chemotherapy</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age &gt;10 years and &lt;40 years;

          -  High-grade nonmetastatic osteosarcoma in pelvis or sacrum;

          -  Diagnosis confirmed histologically and reviewed centrally;

          -  No evidence of metastatic disease with computed tomography scan of the chest and
             radionuclide bone scan, or Positron Emission Tomography (PET/CT) within 2 weeks of
             entry;

          -  No prior therapy;

          -  Eastern Cooperative Oncology Group performance status 0-1;

          -  Life expectancy &gt;3 months;

          -  Adequate renal, hepatic, and hemopoietic function;

        Exclusion Criteria:

          -  Previously treated by chemotherapy or unplanned surgery in other hospital;

          -  Have had other kinds of malignant tumors at the same time;

          -  Uncontrolled complications, such as diabetes mellitus and so on;

          -  Intravascular tumor thrombus on enhanced CT or magnetic resonance (MR);

          -  Unresectable disease evaluated by surgeons.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>10 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wei Guo</last_name>
    <role>Principal Investigator</role>
    <affiliation>Peking University People's Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jie Xu, M.D.</last_name>
    <phone>86 15901040835</phone>
    <email>xujie_pkuph@sina.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Xie Lu, M.D.</last_name>
    <phone>86 13401044719</phone>
    <email>sweetdoctor@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Peking University People's Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100034</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jie Xu, M.D.</last_name>
      <phone>86 15901040835</phone>
      <email>xujie_pkuph@sina.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 26, 2017</study_first_submitted>
  <study_first_submitted_qc>December 1, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">December 4, 2017</study_first_posted>
  <last_update_submitted>December 1, 2017</last_update_submitted>
  <last_update_submitted_qc>December 1, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 4, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Peking University People's Hospital</investigator_affiliation>
    <investigator_full_name>GUO WEI</investigator_full_name>
    <investigator_title>Director of Musculoskeletal Tumor Center</investigator_title>
  </responsible_party>
  <keyword>osteosarcoma</keyword>
  <keyword>pelvis</keyword>
  <keyword>sacrum</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteosarcoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liposomal doxorubicin</mesh_term>
    <mesh_term>Isophosphamide mustard</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Ifosfamide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>Undecided</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

